MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease

1989 ◽  
Vol 1 (4) ◽  
pp. 243-254 ◽  
Author(s):  
Monique Zreika ◽  
J. R. Fozard ◽  
M. W. Dudley ◽  
Ph. Bey ◽  
I. A. McDonald ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Type B ◽  
Irreversible Inhibitor ◽  
Monoamine Oxidase Type B

scholarly journals Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

2020 ◽  
Vol 76 (12) ◽  
pp. 1731-1743
Author(s):  
Caroline D. Binde ◽  
Ingunn F. Tvete ◽  
Jørund I. Gåsemyr ◽  
Bent Natvig ◽  
Marianne Klemp
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Comparative Effectiveness ◽  
Dopamine Agonists ◽  
Relative Effectiveness ◽  
Type B ◽  
Mao B ◽  
Treatment Comparison ◽  
Monoamine Oxidase Type B

Abstract Purpose To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson’s disease. Methods We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson’s disease. We extracted and pooled data from included clinical trials in a joint model allowing both direct and indirect comparison of the seven drugs. We considered dopamine agonists and MAO-B inhibitors given as monotherapy or in combination with levodopa. Selected endpoints were change in the Unified Parkinson’s Disease Rating Scale (UPDRS) score, serious adverse events and withdrawals. We estimated the relative effectiveness of each dopamine agonist and MAO-B inhibitor versus comparator drug. Results Altogether, 79 publications were included in the analysis. We found all the investigated drugs to be effective compared with placebo when given as monotherapy except safinamide. When considering combination treatment, the estimated relative effects of selegiline, pramipexole, ropinirole, rotigotine, cabergoline, rasagiline and safinamide were 2.316 (1.819, 2.951), 2.091 (1.889, 2.317), 2.037 (1.804, 2.294), 1.912 (1.716, 2.129), 1.664 (1.113, 2.418), 1.584 (1.379, 1.820) and 1.179 (1.031, 1.352), respectively, compared with joint placebo and levodopa treatment. Conclusions Dopamine agonists were found to be effective as treatment for Parkinson’s disease, both when given as monotherapy and in combination with levodopa. Selegiline and rasagiline were also found to be effective for treating Parkinson’s disease, and selegiline was the best option in combination with levodopa among all the drugs investigated.

scholarly journals Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

BMJ ◽  
2004 ◽  
Vol 329 (7466) ◽  
pp. 593 ◽  
Author(s):  
Natalie J Ives ◽  
Rebecca L Stowe ◽  
Joanna Marro ◽  
Carl Counsell ◽  
Angus Macleod ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Meta Analysis ◽  
Type B ◽  
Randomised Trials ◽  
Early Parkinson’S Disease ◽  
Monoamine Oxidase Type B

scholarly journals Using monoamine oxidase type B inhibitors in Parkinson's disease

BMJ ◽  
2004 ◽  
Vol 329 (7466) ◽  
pp. 581-582 ◽  
Author(s):  
Yoav Ben-Shlomo ◽  
Kailash Bhatia
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Type B ◽  
Monoamine Oxidase Type B
Sign in / Sign up

Export Citation Format

Share Document